A research team at Yale University says dialysis could prevent the development of Nephrogenic Systemic Fibrosis after receiving a gadolinium-based MRI contrast agent.

According to the Yale research team, which includes the world's foremost authority on Nephrogenic Systemic Fibrosis, dialysis should be aggressively used as soon as possible after MRI in renal patients. Phillip Kuo, who worked with the Yale team, said he and his colleagues believe that the best way to manage NSF is to do everything possible to prevent it.

"Research has shown that gadolinium can hang around for a long time in the circulation of patients ... who are on dialysis," Kuo said. "One study found [gadolinium] can linger in the skin up to a year after contrast administration. It is unlikely that dialysis will effectively remove gadolinium from the skin and other tissues. On the other hand, it takes time for the contrast agent to get into the skin and other tissues, and that's why we're recommending hemodialysis as soon as possible."

If you have developed Nephrogenic Systemic Fibrosis after being administered a gadolinium-based MRI contrast agent, please contact the Gadolinium Lawsuit Lawyers of Williams Kherkher by calling 800-761-3187.